

For Immediate Release
Alembic Pharmaceuticals Limited
Consolidated Results for Quarter/ Year ended
31.03.2014

Editors Synopsis

Quarter ended 31st March 2014

- **Net sales up by 23% to Rs 465.2 crores against Rs 378.4 crores in the corresponding quarter last year**
- **Profit before tax up by 46% to Rs 80.8 crores against Rs 55.2 crores in the corresponding quarter last year**
- **Net profit after tax up by 40% to Rs 61.3 crores against Rs 43.7 crores in the corresponding quarter last year**
- **EBITDA margins is 19.6% at Rs 91.3 crores against 17.3% at Rs 65.6 crores in the corresponding quarter last year**

Year ended 31st March 2014

- **Net sales up by 22% to Rs 1868.4 crores against Rs 1526.0 crores last year**
- **Profit before tax up by 51% to Rs 310.6 crores against Rs 206.4 crores last year**
- **Net profit after tax up by 43% to Rs 235.5 crores against Rs 165.3 crores last year**
- **EBITDA margins is 19.2% at Rs 357.7 crores against 16.5% at Rs 252.0 crores last year**

Vadodara, 28th April, 2014

Alembic Pharmaceuticals Limited reported a 23% increase in revenues to Rs 465.2 crores for the quarter ended 31st March 2014, compared to Rs 378.4 crores in the corresponding quarter last year.

The Company posted 46% growth in profit before tax at Rs. 80.8 crores for the quarter ended 31st March 2014 against Rs 55.2 crores posted in corresponding quarter last fiscal.

The net profit grew by 40% at Rs 61.3 crores for the quarter ended 31st March 2014 against Rs 43.7 crores in corresponding quarter last fiscal.

EBIDTA margins for quarter ended 31st March 2014 up at 19.6% to Rs 91.3 crores from 17.3% at Rs 65.6 crores for corresponding quarter last year.

The company also reported 22% increase in revenue for Year ended 31st March 2014 to Rs 1868.4 crores against Rs 1526.0 crores for last year.

The company also posted 51% growth in profit before tax at Rs. 310.6 crores for Year ended 31st March 2014 against Rs. 206.4 crores for last year. The Company also reported 43% growth in net profit for Year ended 31st March 2014 at Rs. 235.5 crores against Rs. 165.3 crores in last year.

Dividend

The Board has recommended dividend on equity shares at Rs 3.00 per share i.e. 150% for 13-14 (P.Y. Re. 2.50 per share i.e. 125%)

India Branded Formulations Business

The India Branded formulations business posted sales of Rs. 199.5 crores against Rs. 175.3 crores with a 14% growth over the corresponding quarter of the previous year.

The India Branded formulations business posted sales for Year ended 31st March 2014 of Rs. 850.6 crores against Rs. 748.4 crores with a 14% growth over the previous year.

As per ORG IMS, Alembic has market share of 1.73% (MAT-Mar 14). Gestofit has featured as Company's 5th brand in top 300 brands list of IMS-ORG.

Specialty and Acute segments grew by 17% and -3% respectively in current years (MAT-Mar 14) versus Industry growth rate of 11% and 3% respectively.

International Generics

International Generic Formulation posted growth of 76% and posted sales of Rs. 136.7 crores against Rs. 77.7 crores over the corresponding quarter last year.

International Generic formulations business posted sales for Year ended 31st March 2014 of Rs. 468.4 crores against Rs. 235.8 crores with a 99% growth over the previous year.

During the quarter 1 ANDA application and for the year 4 ANDA applications were filed taking cumulative ANDA filings of the Company to 61. During the quarter 1 ANDA approval and for the year 8 ANDA approvals were received taking cumulative ANDA/NDA approvals to 32 (including 4 tentative approvals). During the quarter 2 DMF applications and for the year 6 DMF applications were filed taking cumulative DMF filings of the Company to 66.

Summary of Total Revenue is as under:

(Rs. in Lacs)

Particulars	Q4 FY14	Q4 FY13	% Change	FY 13-14	FY 12-13	% Change
Formulation						
India Branded	19945	17531	14%	85064	74838	14%
India Generics	2867	2979	(-) 4%	12071	12624	(-) 4%
International Branded	1759	1528	15%	7360	5577	32%
International Generics	13665	7766	76%	46837	23577	99%
API	8098	7867	3%	33885	35056	(-) 3%
Export Incentives	188	165	-	1624	928	-
Total	46522	37836	23%	186841	152600	22%

The Profit break-up is as under:

(Rs. in Lacs)

Particulars	Q4 FY14	Q4 FY13	% Change	FY 13-14	FY 12-13	% Change
Operating Income	9129	6558	39%	35771	25196	42%
Profit Before Tax	8078	5518	46%	31060	20635	51%
Net Profit after Tax	6129	4365	40%	23550	16525	43%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 4000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Alembic Pharmaceuticals Limited

Ajay Kumar Desai

Phone: +91 22 – 306 11681

Email: ajay.desai@alembic.co.in

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in